The Austria-based biotech company is working on the vaccine in conjunction with the Institut Pasteur in France. The research institute holds extensive rights to the new vaccine through a licensing deal with the company.
The Zika vaccine is based on previous technology the biotech used to make a measles vaccine.
Erich Tauber, MD, CEO of Themis Bioscience, says the vaccine’s development will benefit from the technology’s proven track record for immunizing against measles.
More articles on supply chain:
Medtronic invests $20M in Mazor Robotics
FDA panel endorses Amgen’s biosimilar version of Humira
GE stakes claim on cell therapy market with Biosafe acquisition
